Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation
Discover Oncology · 08.05.2025 · 16 (1)
DOI: 10.1007/s12672-025-02489-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 08.05.2025. Verfasst von Shirin Tavakoli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Lymphoma, a cancer with poor prognosis is a growing global health challenge that encompasses two primary types, Hodgkin (HL) and non-Hodgkin lymphoma (NHL), each further divided into various subtypes with distinct biological behaviors. Conventional therapeutic strategies include chemotherapy, radiation, surgery, and autologous hematopoietic stem cell transplantation (auto-HSCT). Natural killer (NK) cells exhibit intrinsic cytotoxicity against tumor cells without the need for prior immunization or activation. In this prospective clinical trial, we evaluated the feasibility of allogeneic NK cell therapy in patients with high-risk lymphoma who had a poor prognosis. Each patient received 1 × 107 NK cells/kg infusion without interleukin-2 (IL-2) supplementation. Therapy was tolerated without graft-versus-host-disease, cytokine release syndrome, or neurotoxicity. During the follow-up period, 7 had complete responses (CR) (87.5%) and one case exhibited stable disease (SD) (12.5%). In summary, our investigations support the development of allogeneic NK cellular therapies for advanced lymphoma to overcome chemoresistance. Therapeutic efficacy may be further improved by disrupting the immunosuppressive environment and infusion of exogenous IL-15. This approach presents a promising and pragmatic strategy for managing high-risk lymphoma post-HSCT. Future research should focus on optimizing NK cell dosages and infusion frequency to maximize treatment effectiveness.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Applied Cell Sciences, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
- Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
- Department of Immunology, Faculty of Medicine, Tabriz University of Medical Science, Tabriz, Iran.
- Department of Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
- Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. barkhordarm.n@gmail.com.
Zitieren
APA
Tavakoli, S., Samareh-Salavatipour, M., Mardi, A., Salehi-Shadkami, H., Vaezi, M., Barkhordar, M., & Ahmadvand, M. (2025). Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation. Discover Oncology, 16(1). https://doi.org/10.1007/s12672-025-02489-0
Vancouver
Tavakoli S, Samareh-Salavatipour M, Mardi A, Salehi-Shadkami H, Vaezi M, Barkhordar M, et al. Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation. Discover Oncology. 2025;16(1). doi:10.1007/s12672-025-02489-0
BibTeX
@article{Tavakoli2025,
author = {Tavakoli, Shirin and Samareh-Salavatipour, Maryam and Mardi, Amirhossein and Salehi-Shadkami, Hossein and Vaezi, Mohammad and Barkhordar, Maryam and Ahmadvand, Mohammad},
title = {Evaluating the safety and feasibility of allogeneic NK cell infusion in high-risk lymphoma patients post-autologous stem cell transplantation},
journal = {Discover Oncology},
year = {2025},
volume = {16},
number = {1},
doi = {10.1007/s12672-025-02489-0}
}
EUVIMED